• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.西班牙采集的葡萄球菌血分离株的 TR-700（替考拉宁）比较活性。
Antimicrob Agents Chemother. 2010 May;54(5):2212-5. doi: 10.1128/AAC.01653-09. Epub 2010 Feb 22.
2
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.2008 年至 2011 年，美国医院检测到对利奈唑胺、达托霉素或万古霉素敏感性降低的葡萄球菌的抗菌活性。
Antimicrob Agents Chemother. 2013 Jul;57(7):3178-81. doi: 10.1128/AAC.00484-13. Epub 2013 Apr 29.
3
In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.替考拉宁对当代全球范围内金黄色葡萄球菌分离株的体外活性研究。
Antimicrob Agents Chemother. 2010 Jun;54(6):2704-6. doi: 10.1128/AAC.00301-10. Epub 2010 Apr 12.
4
In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.2006-2008 年成人耐甲氧西林金黄色葡萄球菌血培养分离株的体外药敏分析：利奈唑胺、替加环素和达托霉素的活性按万古霉素 MIC 分层分析。
J Microbiol Immunol Infect. 2011 Oct;44(5):346-51. doi: 10.1016/j.jmii.2011.01.037. Epub 2011 Jan 20.
5
In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.替加环素（TR-700）对耐利奈唑烷葡萄球菌的体外活性。
J Antimicrob Chemother. 2012 Jan;67(1):167-9. doi: 10.1093/jac/dkr403. Epub 2011 Sep 27.
6
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.在一种小鼠大腿感染模型中，研究了新型噁唑烷酮类抗生素磷酸托唑烷（TR-701）对甲氧西林敏感和耐药金黄色葡萄球菌菌株的体内药效学。
Antimicrob Agents Chemother. 2011 Jul;55(7):3453-60. doi: 10.1128/AAC.01565-10. Epub 2011 Apr 18.
7
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.头孢洛林对耐甲氧西林金黄色葡萄球菌（MRSA）中达托霉素、利奈唑胺或万古霉素低水平耐药株，以及具有明确 SCCmec 型别的菌株的活性。
Int J Antimicrob Agents. 2014 Apr;43(4):323-7. doi: 10.1016/j.ijantimicag.2013.11.005. Epub 2013 Dec 11.
8
In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.体外研究中磷酸替加环素（TR-701）治疗复杂性皮肤和皮肤软组织感染的 2 期临床试验中分离的革兰阳性菌临床分离株的活性和微生物学疗效。
Antimicrob Agents Chemother. 2012 Sep;56(9):4608-13. doi: 10.1128/AAC.00458-12. Epub 2012 Jun 11.
9
Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.头孢比普、利奈唑胺、万古霉素和达托霉素对社区获得性和医院获得性耐甲氧西林金黄色葡萄球菌的活性。
Antimicrob Agents Chemother. 2008 Aug;52(8):2974-6. doi: 10.1128/AAC.00257-08. Epub 2008 Jun 2.
10
Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).通过使用恶唑烷酮类药物利奈唑胺和替唑肟（TR-700）进行选择，鉴定出金黄色葡萄球菌菌株中的新型核糖体突变。
Antimicrob Agents Chemother. 2009 Dec;53(12):5265-74. doi: 10.1128/AAC.00871-09. Epub 2009 Sep 14.

引用本文的文献

1
Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis.近期获批抗生素对耐甲氧西林金黄色葡萄球菌（MRSA）菌株的抗菌活性：系统评价和荟萃分析。
Ann Clin Microbiol Antimicrob. 2022 Aug 17;21(1):37. doi: 10.1186/s12941-022-00529-z.
2
In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections.表皮葡萄球菌假体关节感染分离株的替加环素和利奈唑胺的体外活性。
Eur J Clin Microbiol Infect Dis. 2017 Sep;36(9):1549-1552. doi: 10.1007/s10096-017-2966-z. Epub 2017 Mar 22.
3
Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.替加环素治疗皮肤感染的药代动力学药物评价
Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):331-337. doi: 10.1080/17425255.2017.1290080. Epub 2017 Feb 16.
4
Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.替考拉宁：一种新型噁唑烷酮类药物，对多种耐药革兰阳性病原体具有强大的活性。
Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7.
5
Tedizolid phosphate.磷酸泰地唑胺
Hosp Pharm. 2014 Nov;49(10):961-71. doi: 10.1310/hpj4910-961.
6
Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.磷酸特地唑胺在急性细菌性皮肤感染治疗中的潜在作用。
Drug Des Devel Ther. 2013 Apr 3;7:243-65. doi: 10.2147/DDDT.S30728. Print 2013.
7
Newer antibacterials in therapy and clinical trials.治疗及临床试验中的新型抗菌药物。
N Am J Med Sci. 2012 Nov;4(11):537-47. doi: 10.4103/1947-2714.103312.
8
Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.新恶唑烷酮类药物替加环素磷酸盐与利奈唑胺在中性粒细胞减少的金黄色葡萄球菌肺炎小鼠模型中的比较药效学研究。
Antimicrob Agents Chemother. 2012 Nov;56(11):5916-22. doi: 10.1128/AAC.01303-12. Epub 2012 Sep 10.
9
In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.体外研究中磷酸替加环素（TR-701）治疗复杂性皮肤和皮肤软组织感染的 2 期临床试验中分离的革兰阳性菌临床分离株的活性和微生物学疗效。
Antimicrob Agents Chemother. 2012 Sep;56(9):4608-13. doi: 10.1128/AAC.00458-12. Epub 2012 Jun 11.
10
Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.替加环素、利奈唑胺和万古霉素经上皮衬液暴露于耐甲氧西林金黄色葡萄球菌的体内疗效比较在小鼠肺炎模型中。
Antimicrob Agents Chemother. 2012 May;56(5):2342-6. doi: 10.1128/AAC.06427-11. Epub 2012 Feb 21.

本文引用的文献

1
Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.首次报告耐利奈唑酮的金黄色葡萄球菌爆发与 cfr 基因介导的利奈唑酮耐药有关。
Clin Infect Dis. 2010 Mar 15;50(6):821-5. doi: 10.1086/650574.
2
Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.左氟沙星年度效价和光谱评估计划：利奈唑胺监测计划 2008 年结果。
Diagn Microbiol Infect Dis. 2009 Dec;65(4):404-13. doi: 10.1016/j.diagmicrobio.2009.10.001.
3
Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.核糖体蛋白 L3 中的突变与临床来源的葡萄球菌对唑烷酮类药物的耐药性有关。
Antimicrob Agents Chemother. 2009 Dec;53(12):5275-8. doi: 10.1128/AAC.01032-09. Epub 2009 Oct 5.
4
Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).通过使用恶唑烷酮类药物利奈唑胺和替唑肟（TR-700）进行选择，鉴定出金黄色葡萄球菌菌株中的新型核糖体突变。
Antimicrob Agents Chemother. 2009 Dec;53(12):5265-74. doi: 10.1128/AAC.00871-09. Epub 2009 Sep 14.
5
In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.新型恶唑烷酮类抗菌药物前体药物TR - 701的活性成分TR - 700的体外活性。
Antimicrob Agents Chemother. 2009 Aug;53(8):3236-9. doi: 10.1128/AAC.00228-09. Epub 2009 Jun 15.
6
ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.利奈唑胺耐药性的ZAAPS国际监测项目（2007年）：来自23个国家5591株革兰氏阳性临床分离株的结果
Diagn Microbiol Infect Dis. 2009 Jun;64(2):191-201. doi: 10.1016/j.diagmicrobio.2009.03.001.
7
TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.TR-700对革兰氏阳性病原体的体外活性及耐药突变频率
J Antimicrob Chemother. 2009 Apr;63(4):716-20. doi: 10.1093/jac/dkp021. Epub 2009 Feb 13.
8
Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.恶唑烷酮TR-700对利奈唑胺敏感及耐药葡萄球菌和肠球菌的活性。
J Antimicrob Chemother. 2009 Apr;63(4):713-5. doi: 10.1093/jac/dkp002. Epub 2009 Jan 22.
9
In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.前药TR-701的抗菌部分TR-700对耐利奈唑胺菌株的体外活性。
Antimicrob Agents Chemother. 2008 Dec;52(12):4442-7. doi: 10.1128/AAC.00859-08. Epub 2008 Oct 6.
10
First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.美国分离出的人葡萄球菌临床分离株中cfr介导的对利奈唑胺耐药性的首次报告。
Antimicrob Agents Chemother. 2008 Jun;52(6):2244-6. doi: 10.1128/AAC.00231-08. Epub 2008 Apr 7.

西班牙采集的葡萄球菌血分离株的 TR-700（替考拉宁）比较活性。

Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.

机构信息

Servicio de Microbiología Clínica, Hospital Clínico San Carlos, Madrid, Spain.

出版信息

Antimicrob Agents Chemother. 2010 May;54(5):2212-5. doi: 10.1128/AAC.01653-09. Epub 2010 Feb 22.

DOI:10.1128/AAC.01653-09
PMID:20176900
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2863658/
Abstract

The in vitro activity of TR-700 (torezolid) was evaluated against a collection of 660 staphylococcal blood isolates. TR-700 showed excellent activity against all the staphylococci tested. The MIC(50) and MIC(90) values of TR-700, linezolid, daptomycin, and vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) isolates were 0.25 and 0.5, 2 and 4, 0.5 and 0.5, and 1 and 2 microg/ml, respectively. TR-700 demonstrated greater in vitro potency than linezolid against staphylococci, including linezolid-resistant and vancomycin-nonsusceptible strains, and was 32-fold more active than linezolid against the seven cfr-positive MRSA strains tested.

摘要

TR-700（替唑利定）的体外活性对 660 株葡萄球菌血培养分离株进行了评估。TR-700 对所有测试的葡萄球菌均表现出优异的活性。TR-700、利奈唑胺、达托霉素和万古霉素对耐甲氧西林金黄色葡萄球菌（MRSA）分离株的 MIC（50）和 MIC（90）值分别为 0.25 和 0.5、2 和 4、0.5 和 0.5、1 和 2μg/ml。TR-700 对葡萄球菌的体外效力大于利奈唑胺，包括利奈唑胺耐药和万古霉素不敏感株，对 7 株 cfr 阳性 MRSA 株的活性比利奈唑胺高 32 倍。